Processa PharmaceuticalsPCSA +9.64%28 PB Ratio is 2.28 as of Jul. 10, 2026. GuruFocus rates PCSA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,227 Biotechnology companies, Processa Pharmaceuticals ranks better than 62.75% on this metric.
The historical rank and industry rank for Processa Pharmaceuticals's PB Ratio or its related term are showing as below:
PCSA'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 2.36
Current: 2.27
During the past 13 years, Processa Pharmaceuticals's highest PB Ratio was 2.36. The lowest was 0.00. And the median was 0.00.
PCSA's PB Ratio is ranked better than 62.75% of 1227
companies
in the Biotechnology industry
Industry Median: 2.95
vs PCSA: 2.27
During the past 12 months, Processa Pharmaceuticals's average Book Value Per Share Growth Rate was -94.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -79.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -71.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Processa Pharmaceuticals was 180.10% per year. The lowest was -79.00% per year. And the median was -41.20% per year.
Back to Basics: PB Ratio
Processa Pharmaceuticals (NAS:PCSA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Processa Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Processa Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Processa Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Processa Pharmaceuticals (PCSA) has a PB Ratio of 2.28 as of Jul. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Processa Pharmaceuticals and its competitors. According to the industry distribution chart, Processa Pharmaceuticals ranks #457 out of 1227 companies in the Biotechnology industry, placing it in the top 37.2%.
Is Processa Pharmaceuticals' PB Ratio too high?
Processa Pharmaceuticals' current PB Ratio is 2.28. The Biotechnology industry median PB Ratio is 2.95. Processa Pharmaceuticals' value of 2.28 is 22.7% below this industry median. Based on the distribution chart, Processa Pharmaceuticals ranks #457 out of 1227 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Processa Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Processa Pharmaceuticals' PB Ratio compare to ELAB and MBIO?
According to the Biotechnology industry distribution chart, Processa Pharmaceuticals ranks #457 out of 1227 companies for PB Ratio. This puts Processa Pharmaceuticals in the upper half of its industry. The industry median PB Ratio is 2.95. Processa Pharmaceuticals' value of 2.28 is 22.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Processa Pharmaceuticals's current PB Ratio of 2.28 is 22.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Processa Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Processa Pharmaceuticals's current PB Ratio is 2.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Processa Pharmaceuticals stock overvalued right now?
Processa Pharmaceuticals (PCSA) has a current PB Ratio of 2.28. The current PB Ratio is 2.28 and 22.7% below the Biotechnology industry median of 2.95. Processa Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current PB Ratio is 2.28 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
28GF Score
Get the complete analysis for PCSA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCSA has been successfully added to your 
